WO2002036153A1 - Expression potentiator for protein synthesis regulatory gene - Google Patents
Expression potentiator for protein synthesis regulatory gene Download PDFInfo
- Publication number
- WO2002036153A1 WO2002036153A1 PCT/JP2001/008390 JP0108390W WO0236153A1 WO 2002036153 A1 WO2002036153 A1 WO 2002036153A1 JP 0108390 W JP0108390 W JP 0108390W WO 0236153 A1 WO0236153 A1 WO 0236153A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ifn
- gene
- expression
- subtype
- protein synthesis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to a novel expression enhancer of a protein synthesis-suppressing gene, specifically, subtype ⁇ 2 and subtype ⁇ 8 (hereinafter referred to as “IFNJ, interferon ⁇ (“ IFN- ⁇ ), a subtype ⁇ 2 and a subtype ⁇ 8 in human interferon ⁇ are abbreviated as FN-a2J and “IFN-a8J,” respectively, as active ingredients.
- IFNJ interferon ⁇
- IFN-a8J interferon ⁇
- IFN is a generic name given to a group of proteins with antiviral activity that are secreted extracellularly when vertebrate cells are subjected to external stimuli such as virus infection or antigen stimulation.
- IFN- ⁇ IFN- ⁇
- IFN-r IFN-r are roughly classified into three types. IFN is known to have various physiological activities such as cell growth inhibitory activity and antitumor activity in addition to pile virus activity. Isolation and identification of IFN receptors have been progressed.
- IFN- and IFN- share a common receptor, while it is known that there is a different receptor for IFN- :.
- IFN the expression of bioactivity by IFN starts with the stimulation of susceptible cells by IFN, i.e., the binding of IFN to the IFN receptor expressed on the cell surface, followed by The intracellular signal transduction system operates, and in response to that information, specific gene expression occurs in the cell. It is achieved by making various changes. In recent years, the isolation and identification of molecules involved in this intracellular signal transduction system has been rapidly progressing.
- 2 ′, 5′-oligoadenylic acid As a product (protein) of a gene whose expression is induced by 2 ′, 5 ′ one-year-old rigoadenylate synthase (hereinafter, “2 ′, 5′-oligoadenylic acid” is abbreviated as “2-5AJ”), 2 This includes RNA, protein-dependent kinase (hereinafter abbreviated as “PKR”), Mx protein, class I and class II MHC molecules, ⁇ -2 microglobulin, guanylate binding protein, and meta-chothonein. I have. They are often also induced by IFN-r.
- PLR protein-dependent kinase
- 2-5A synthase which is an enzyme that suppresses protein synthesis, PKR, and Mx protein cause abnormalities such as tumorigenesis of cells and infection of cells with viruses. It plays a direct role in suppressing such abnormalities in the affected cells.
- MHC molecules and jS-2 microglobulin are proteins related to the function of the immune system in the living body, and are indirectly involved in removing tumors and viruses from the living body through the activation of the immune system in the living body . The relationship between guanylate-binding protein and metallothionein and the expression of bioactivity by IFN has not been elucidated at present.
- IFN has been receiving great promise as a medicine, for example, when it was first called a “dream new drug”. However, contrary to that expectation, certain types of diseases have not been as effective as expected.
- IFNs are based on the conditions that make them work for each type or subtype, such as the target cell, the type of virus infecting the cell, and the combination of IFN used. Although the types and strengths of the effects exerted by such factors have different characteristics, the optimal conditions for achieving the desired effect in each situation have been completely elucidated. It is thought that there is not.
- IFN- ⁇ , ⁇ , and r For a comparison of gene expression enhancing effects between IFN- ⁇ , ⁇ , and r, see, for example, P. L. Triotzi et al., “Journal of biological” response, “Modifiers,” Vol. 5, No. 6, pages 562 to 570 (1986), and James Kossia et al., Journal of Interferon Research, Vol. 8, No. 1, pages 113 to 127 ( 1988), there are reports that IFN-: is inferior to IFN- and IFN- in its ability to induce the expression of 2-5 ⁇ synthase gene and PKR gene. .
- IFN- unlike IFN- ⁇ IFN-r, has at least a dozen or more subtypes, and significantly exerts the effect of inducing IFN-induced gene expression.
- IFN- ⁇ IFN-r has at least a dozen or more subtypes, and significantly exerts the effect of inducing IFN-induced gene expression.
- the present inventors have determined that the product of a protein synthesis-inhibiting gene whose expression is induced by IFN is directly involved in exerting a certain action by IFN, and that the gene Focusing on the fact that studies aimed at optimizing the combination of IFN- ⁇ subtypes in the induction of expression of IGFN- ⁇ have not yet been made, the subtypes of IFN- ⁇ that significantly enhance the expression of the gene have been noted. The combination was found, and it was thought that further effective use of IFN as a medicine could be achieved.
- an object of the present invention is to identify a combination of subtypes of IFN-cd that significantly enhance the expression of a protein synthesis-suppressing gene, and to enhance the expression of a gene containing such a subtype as an active ingredient.
- the present inventors used various isolated subtypes of human I FN- ⁇ to separate individual specimens from cells. The effect shown We investigated a wide range of cases, alone and in combination as appropriate, and compared the results with each other.
- the present invention provides a protein synthesis inhibitor gene expression enhancer comprising IFN- ⁇ 2 and IFN- ⁇ 8, which are subtypes of human IFN- ⁇ , as active ingredients, and a pharmaceutical product of the enhancer.
- the purpose of the present invention is to solve the above-mentioned problems by providing other uses.
- the present invention makes effective use of IFN- ⁇ 2 and IFN- ⁇ 8, which are subtypes in human IFN- ⁇ (hereinafter, the subtype in human H FN- ⁇ is simply referred to as “subtype j”).
- the present invention relates to an agent for enhancing the expression of a protein synthesis-suppressing gene (hereinafter sometimes referred to as “the expression enhancer of the present invention” or “the enhancer”), which is contained as a component.
- the amino acid sequences of both subtypes both include the signal sequence at the N-terminus, each of which has been recorded under “P32881” 1) are listed in the sequence listing in the present specification. And 2).
- the higher-order structure and the structure of sugar chains other than the amino acid sequence are not important.
- Amino acid sequence power of subtypes H FN- ⁇ is classified as ⁇ , and when compared with the amino acid sequence of the subtype in the known IFN-, the amino acid sequence of SEQ ID NO: 1 or 2 It indicates high homology.
- the amino acid sequences of the subtypes of known human H FNs are described, for example, in J. Allen et al., Journal of Ob, Interferon and Site Force in Research, Vol. 16, 181 to 184. Page (1996) summarizes the original reports reporting individual amino acid sequences.
- IFN-a2 contains a protein having the amino acid sequence of SEQ ID NO: 1 in the sequence listing as well as a protein having an amino acid sequence that differs by one amino acid from this amino acid sequence.
- IFN- ⁇ 8 includes a protein having the amino acid sequence of SEQ ID NO: 2 in the sequence listing, and a protein having a sequence having four or six amino acids different from this amino acid sequence. It has been shown that two types of proteins are included.
- IFN-NA2 and IFN- ⁇ 8 are not limited to the amino acid sequence shown in SEQ ID NO: 1 or 2, and in the amino acid sequence shown in SEQ ID NO: 1 or 2, usually The amino acid may have an amino acid sequence that is different from 0 or less, preferably 8 or less, more preferably 6 or less.
- the subtype used in the present invention is IFN-2 and IFN-2 as defined above (this source is not limited as long as it is IF IF- ⁇ 8.
- a natural subtype obtained from human cells may be used. Genetic engineering using any of the following types: vertebrate cells including human cells, invertebrate cells, plant cells, prokaryotic cells such as Escherichia coli and Bacillus subtilis, and microorganisms including eukaryotic cells such as yeasts and molds Recombinant subtypes produced by this technique are useful, and are shared with polypeptide chains as IFN- ⁇ 2 and IFN- ⁇ 8 as long as the desired activity is maintained.
- a natural product having a bound water-soluble polymer (described later) and a subtype (hereinafter sometimes referred to as a “modified with a water-soluble polymer”) as an artificial preparation can also be advantageously used.
- repair with water-soluble polymer Subtype as things, example
- a natural subtype that originally has a water-soluble polymer, or an artificially shared water-soluble polymer with a previously prepared natural or recombinant subtype As long as the desired activity is maintained, any of them can be advantageously used, even if they are obtained by binding, but they are modified with water-soluble polymers obtained by artificial methods as described below.
- the subtype is characterized in that when the enhancer is used for a medical application, it is relatively excellent in terms of its high in vivo stability when administered to an applied patient.
- Use of the natural subtype may be advantageous in terms of low antigenicity to the patient to which it is applied.
- recombinant subtypes have the advantage that they can be prepared or obtained at relatively low cost. Therefore, in the implementation of the present invention, it is possible to select and use the one that matches the purpose of use in accordance with the situation in consideration of the properties of each type of subtype as described above.
- Confirmation that the subtype used in the present invention is 1FN- ⁇ 2 or 1FN- ⁇ 8 is determined by the partial amino acid sequence obtained by decoding the desired subtype according to a conventional method, or Isolation is performed by isolating the corresponding cDNA from the source and examining the identity between the amino acid sequence deduced from the results of decoding the base sequence and the corresponding portion of the amino acid sequence of SEQ ID NO: 1 or 2 in the sequence listing. it can.
- IFN-activity (titer, titer) is usually calculated as an international unit (hereinafter sometimes referred to as "IU") by comparison with an IFN- ⁇ international standard sample based on antiviral activity. Is displayed.
- the international standard sample of HI FN-or is provided by the US National Institutes of Health in a state that the package number "Ga23-901-532" is enclosed in a size of 25,000 IU per ampule.
- the antiviral activity can be confirmed by various methods. For example, using the dye uptake method described in J. Imanishi et al., Bigen's Journal, Vol. 24, pp. 108-109 (1998), cytopathy caused by virus to cells can be achieved.
- IFN-activity is measured in IU according to this method using Sindbis virus as a virus and FL cells (ATCC CC-162), an established cell line derived from human amniotic membrane, as cells. it's shown.
- the principle is as follows. First, the concentration X (I UZml) of the above-mentioned international standard sample that inhibits the SPE of Sindbis virus against FL cells by 50% is determined.
- the specific activity IU mg protein
- the protein synthesis-suppressing gene referred to in the present invention refers to the process of protein synthesis in a cell, i.e., the reaction in a cell belonging to either the step of transcription from DNA to mRNA or translation of protein from mRNA. It means a gene encoding a protein having a function of suppressing or inhibiting and whose expression is normally induced by IFN stimulation.
- the transcription step referred to here involves the production of primary transcript RNA from DNA, splicing of RNA, addition of cap structure or addition of polyadenylic acid to RNA, etc. Includes all intracellular reactions produced.
- the translation step referred to above involves so-called “initiation of protein biosynthesis” triggered by binding of liposomes to mRNA, and so-called “linkage of amino acids according to the genetic code on mRNA”. Includes all intracellular reactions that produce a polypeptide having a sequence corresponding to an mRNA, such as "elongation of polypeptide chain” and "terminating protein biosynthesis” at a stop codon on mRNA.
- Specific examples of the protein synthesis-suppressing gene which is an object of the present invention include, for example, a 2-5A synthase gene and a PKR gene.
- 2-5A synthase the product of such a gene, generates 2-5A in cells using ATP as a substrate, and 2-5A converts ribonuclease L, which exists as an inactive form in cells, into an active form. Convert and activate The type of liponuclease L inhibits protein synthesis by degrading RNA.
- PKR phosphorylates the orF subunit of elF-2, which is a factor involved in the initiation of protein biosynthesis as described above, in a double-stranded RNA-dependent manner and inactivates protein synthesis. Inhibits.
- induction of gene expression by stimulation of FN” means that the level of gene expression in a cell in response to stimulation of the cell by IFN is the amount of gene transcription and / or translation of mRNA. It means that it is confirmed as an increase in the amount.
- Gene type-- depending on the type of cell having the gene, the protein synthesis-suppressing gene targeted by the present invention preferably has an expression level of 1.5-fold or more due to IFN stimulation. In some cases, it rises by a factor of 2 or more, and even more preferably by a factor of 2.5 or more.
- ordinary quantitative RT-PCR or Northern blotting may be used.
- nucleotide sequences of the genes in the above examples were registered with the access codes shown in Table 1 below in the nucleic acid database “GenBank” by the National Center for Biotechnology, Inc. (USA), respectively. Therefore, if these methods are carried out using primers or probes prepared based on this information, the transcription amount of the target gene can be quantitatively detected according to the sensitivity.
- a method for specifically quantifying the protein which is the expression product of the gene can be used. For example, a specific antibody against the expression product of the gene of interest is used.
- the expression product of the target gene has enzymatic activity, use an immunological method (such as immunoassay) if available, and use the specified enzyme activity measurement method if the expression product of the target gene has enzymatic activity.
- an immunological method such as immunoassay
- the specified enzyme activity measurement method if the expression product of the target gene has enzymatic activity.
- the expression-enhancing agent of the present invention contains IFN-2 and IFN- ⁇ 8 as active ingredients, and the sum of the expression-inducing effects of the respective subtypes alone on the protein synthesis-suppressing gene, or the sum of such effects. It is characterized by exerting a synergistic effect on the induction of the expression of the protein synthesis suppressing gene, ie, an effect that clearly exceeds the expected effect. This synergistic effect can be confirmed based on the transcription amount and translation amount obtained as described above.
- the expression product of the protein synthesis-suppressing gene referred to in the present invention is usually a major functional molecule having a biological activity exhibited by IFN- on susceptible cells.
- the apoptosis-inducing activity is achieved by causing the enhancer to act on cancer cells such as liver cancer cells to induce intracellular DNA fragmentation, a characteristic phenomenon of apoptosis, and expression of apoptosis-related molecules such as Fas. It can also be confirmed by a conventional method of quantitative observation.
- the enhancer also synergistically and markedly enhances the expression-inducing action of 1 FN-induced protein synthesis-suppressing gene. Therefore, it can also be used as an enhancer of IFN- induced expression of the gene. Can be used.
- the synergistic effect of the enhancer confirmed as described above is expressed as the sum of the expression inducing effects of IFN-1 and IFN-1 ⁇ 8 alone or the value assumed to be the sum as numerical value 1.
- the enhancer usually exerts an expression inducing action of at least 1.2, and more preferably at least 1.5.
- this synergistic effect For example, it can be confirmed by the multivariate analysis described in Tea “Sea” Butterfly, “Synergism” and “Antagonism” in “Chemotherapy” (1991, published by Academic Press), pp. 61-102. According to this method, as shown in Table 2 below, the presence / absence of synergy and the strength of two different drugs can be quantified and evaluated as a combination index (CI).
- the CI of the enhancer is usually less than 0.9, and preferably less than 0.85, if appropriate, depending on the gene of interest.
- the activity ratio between IFN-or 2 and IFN- ⁇ 8 in the expression enhancer of the present invention exerts such a synergistic effect on at least one of the protein synthesis suppressing genes.
- the preferable abundance ratio of IFN-2 and IFN- ⁇ 8 in the expression enhancer of the present invention for remarkably exhibiting the expected synergistic action is expressed as a weight ratio of both, and the purification degree of the subtype used is expressed.
- a standard protein quantification method such as the oral method or the UV absorption method, uses the standard sample as the control for the target subtype and a simple protein containing substantially no sugar chains in the state of isolation. (Weight corresponding to the polypeptide chain portion).
- the expression enhancer of the present invention may contain other subtypes as long as the synergy between IFN- ⁇ 2 and IFN- ⁇ 8 is not lost.
- the like IFN-[alpha] 1 and IFN-[alpha] 7 if the content is relatively low, usually, it does not affect the synergistic effect of IFN-2 and IFN-alpha 8 and, the up strong agent Can be contained.
- the percentage of the total amount of IFN- ⁇ 2 and IFN- ⁇ 8 to the total amount of IFN- ⁇ is usually 90% or more in terms of international units, preferably 95%, depending on the type of gene or cell type of interest. %, More preferably 980/0 or more, has a relatively significant synergy in inducing gene expression irrespective of the types of subtypes other than IFN-2 and IFN- ⁇ 8. There is a feature that exerts an effect.
- the activity ratio between IFN- ⁇ 2 and IFN- ⁇ 8 in the expression enhancer of the present invention and the percentage of the sum of IFN-2 and IFN- ⁇ 8 relative to the total amount of IFN- ⁇ can be determined as follows. . That is, first, the enhancer is purified using an anti-human HFN- ⁇ antibody column or the like to a state in which the contained protein substantially consists of only the subtype of IFN- ⁇ . Next, the purified sample is subjected to a conventional method for separating subtypes of 1FN- ⁇ , such as ion exchange chromatography and reverse phase chromatography, to fractionate and isolate each individual subtype. If necessary, the isolated subtype is confirmed to be one of the subtypes in human HFN-a by amino acid sequence analysis, etc.
- the isolated subtype is simply determined.
- the specific activity (IUZmg protein) of each isolated subtype is determined separately, and the above IFN-purified sample is analyzed separately by high-performance liquid chromatography, etc., which separates each IFN- ⁇ subtype. And the resulting The abundance ratio (weight ratio) of IFN-a2 and IFN-a8 to the total amount of IFN-a is determined based on the peak area ratio in the chromatogram.
- the target activity ratio can be calculated in terms of international units.
- the expression enhancer of the present invention can be prepared by various methods.
- the natural forms of IFN- ⁇ 2 and IFN- ⁇ 8 cause human cells to produce IFN-, and IFN- ⁇ 2 and IFN- ⁇ 8 must be collected from the organism, and the enhancer must be prepared using the collected material.
- the human cell used here may be a cell that produces one or both of IFN-2 and IFN- "8 by stimulation with an appropriate inducer, and two or more cells may be appropriately used depending on their production ability.
- leukocytes such as lymphocytes and monocytes isolated from human living organisms, macrophages, and established cells of human origin such as human lymphoblastoid cells.
- BALL a kind of human lymphoblastoid cells, described in Esseraki et al., “Journal“ Saibu ”National” Cancer — “Institute”, Vol. 59, p. 93 (1977).
- One cell is particularly useful in the practice of the present invention because it produces both subtypes well.
- the cells To produce IFN- ⁇ in human cells, the cells must first be cultured in vitro or in a non-human warm-blooded animal. To grow in vivo. In vitro propagation may be performed by a conventional method for culturing animal cells using an incubator or a fermenter. In vivo culturing is described, for example, in Japanese Patent Publication No. Sho 56-54158.
- IFN- ⁇ is produced by applying an IFN inducing agent to the cells at an appropriate time during or before or after the growth of the cells in vitro or in vivo.
- IFN inducers include, but are not limited to, viruses, double-stranded RNA, bacteria, endotoxin, as well as IFN- ⁇ itself and IFN- ⁇ such as IL-1 and TNF. Site force inducing.
- IFN- ⁇ or its subtypes IFN- ⁇ 2 and IFN- ⁇ 8 are collected from the product of the above-described process that produces IFN- ⁇ .
- Collection of IFN-a can be performed by a conventional method, for example, salting out, dialysis, filtration, centrifugation, concentration, lyophilization, gel filtration chromatography, ion exchange chromatography, affinity chromatography, Appropriate combinations of reverse phase chromatography, isoelectric focusing, electrophoresis and the like are used to collect a desired fraction from the fractionated fraction, for example, a fraction exhibiting the desired antiviral activity, to thereby obtain a desired level.
- An IFN- standard purified to a bell can be obtained.
- the product of the step of producing IFN- ⁇ as described above is first fractionated by chromatography such as affinity chromatography using an anti-IFN- ⁇ antibody as a carrier.
- chromatography such as affinity chromatography using an anti-IFN- ⁇ antibody as a carrier.
- FN-A purified sample substantially free of contaminating proteins other than FN-is obtained is obtained, and then the purified sample is fractionated by ion exchange chromatography, reverse phase chromatography, etc. to separate individual subtypes.
- the purified subtype may be further concentrated, dried, etc., and then processed at a desired activity ratio, or, if necessary, a recombinant subtype or a recombinant subtype described below.
- the activity ratio between IFN-I or 2 and IFN- ⁇ 8 becomes a desired ratio.
- an active ingredient of the enhancer is obtained.
- the activity ratio between IFN- ⁇ ; 2 and IFN- ⁇ 8 is within a desired range, and the purification level does not prevent achievement of the object of the present invention. If the standard reaches up to, this can be used as the active ingredient of the enhancer.
- a commercially available IFN- ⁇ sample such as a research reagent sold by Cosmo Bio Co., Ltd.
- IFN- ⁇ 2 and IFN- or 8 samples isolated as described above are effective.
- a preparation containing both subtypes, purified from such a commercial product, can be used as the active ingredient of the enhancer as it is.
- a DNA encoding a desired subtype is obtained with reference to known information.
- known information For example, Emm 'O'ichi Diaz et al., Journal of Interferon and' Site Power in Research ', Vol. 16, pp. 179-180 (1996)
- a collection of papers reporting DNA encoding various subtypes in human IFN- is also provided.
- Conventional nucleic acid databases are also useful, for example, access codes "J00207" and "X03125" to the nucleic acid database "GenBank” from the National Center for Biotechnology Information (USA).
- the target D can be obtained by applying a conventional method for cloning DNA such as CR using RNA or DNA obtained from an appropriate source. Next, the obtained DNA is inserted into a desired expression vector.
- a replicable vector usually comprises an appropriate base sequence such as a promoter, enhancer, origin of replication, transcription termination site, splicing sequence and / or selection sequence for expressing the DNA of the present invention in each host. .
- a promoter such as a heat shock protein promoter or a promoter disclosed in Japanese Patent Application Laid-Open No. 163368/1992 by the same applicant is used as the promoter, the expression of the DNA in the transformant is externally determined. It will be possible to control artificially by stimulation.
- Such a recombinant DNA is then introduced into a suitable host.
- a suitable host Microorganisms including appropriate and commonly used prokaryotic and eukaryotic cells, cells derived from animals including plants, vertebrates and invertebrates, and animals and plants themselves can be used. Specific examples of animal-derived host cells include, for example, 3T
- COS-1 cells ATCC CR-1650
- HeLa cells ATCC CCL-2
- a clone that produces the desired subtype in the transformant thus obtained may be selected.
- the clone thus obtained is cultured in an appropriate medium, and if necessary, an inducer is added to produce IFN- ⁇ , and the product is used as the natural IFN- ⁇ 2 and IFN- ⁇ described above.
- Purification can be carried out in the same manner as in the preparation method of a8 or according to a conventional method suitable for the host vector used to obtain recombinant IFN- ⁇ 2 and IFN- ⁇ 8.
- a natural or recombinant subtype of interest is prepared by any of the methods described above. Covalently attach water-soluble polymer to selected subtype It may be subjected to a known reaction.
- the water-soluble polymer referred to in the present invention is a substance having a molecular weight of 500 or more, which is essentially constituted by a repetitive structure of the same kind or two or more kinds of monomers, and has a water solubility. And includes natural molecules, synthetic molecules, and partially decomposed products and modified products thereof.
- water-soluble polymer examples include, for example, soluble starch, mycobacterium, dextran, polysucrose, pullulan, ercinan, curdlan, arabia gum, tragacanth gum, guar gum, xanthan gum, power lagenan, hyaluronic acid. Acid, heparin, dalcomannan, chitosan, lipopolysaccharide, polyethylene glycol, polyvinylpyrrolidone, asia mouth siamcoid, asia mouth fetuin, albumin, galactose-modified albumin, polylysine, galactose I-those modification Polylysine, etc.
- the preferred molecular weight in the practice of the present invention depends on the type of the water-soluble polymer used, but is generally from 500 to 10,000,000, more preferably from 10,000,000 to 1,000,000, as the average molecular weight. 000 range.
- a diazo method for example, a diazo method, a peptide method, an alkylation method, a cross-linking method, an amide bond method, etc.
- a known method may be used.
- Japanese Patent Application Laid-Open No. Hei 3-93730 by the same patent applicant and Japanese Patent Application No. 1-162778 by the same patent applicant detail the typical methods, and are advantageously used in the present invention. it can.
- a conventional method of covalently bonding a water-soluble polymer to a desired protein by utilizing the action of transglutaminase can also be advantageously used.
- International Patent Application Publication No. WO Q6 10089 discloses a method utilizing the action of transglutaminase.
- a water-soluble polymer selected according to the purpose includes, for example, ⁇ -aminobenzyl group, ⁇ -aminobenzoyl group, m-aminoanisole group, m-aminoazol group, m-aminobenzyloxymethyl group, 3- (p-aminophenoxy) -1-hydroxypropionyl group, 3- (p-aminom-methyla) Derivatives obtained by introducing an aromatic amino group such as dilino-1-5-chlorotriazinyl group by a known method may be reacted with IFN- ⁇ 2 and / or IFN- ⁇ 8.
- a water-soluble polymer originally having a carboxyl group or a water-soluble polymer into which a carboxyl group has been introduced can be converted into a carboxylic acid such as acid azide, acid chloride, carpoimide, or isocyanate by a conventional method.
- the water-soluble polymer is activated by reacting the water-soluble polymer having an intrinsic hydroxyl group with a cyanuric acid halide to form a cyanuric acid halide-activated water-soluble polymer; Such an activated water-soluble polymer may be reacted with IFN- ⁇ 2 and / or IFN- ⁇ 8.
- a water-soluble polymer obtained by introducing a chloroacetyl group, a bromoacetyl group, an odoacetyl group, a triazinyl halide group, or the like into an appropriate water-soluble polymer by a conventional method is used.
- the high molecular weight alkyl halide derivative may be reacted with IFN-a2 and / or IFN- ⁇ 8.
- IFN- ⁇ 2 and / or IFN- ⁇ 8 and a water-soluble polymer can be used, for example, glutaraldehyde, glyoxal, succinaldehyde, hexamethylene diisocyanate,
- the reaction may be carried out in the presence of a crosslinking reagent such as toluene-1,4-diisocyanate, bisazobenzidine, N, N'-ethylenebismaleimide.
- a water-soluble polymer having an amino group or a water-soluble polymer having an amino group introduced thereinto may be used, for example, by means of bromocetyl bromide, chlorobutyryl chloride, and chloropropyryl chloride.
- An activated water-soluble polymer obtained by reacting with a haloacyl halide such as sodium nilfluoride or ovalvaleryl iodide may be reacted with IFN- ⁇ 2 and / or IFN- ⁇ 8 .
- a water-soluble polymer having an amino group or an amino group is introduced.
- the water-soluble polymer may be reacted with IFN- ⁇ 2 and IFN- ⁇ 8 in the presence of a transglutaminase of a desired origin.
- the reaction conditions may be any as long as the transglutaminase-catalyzed transfer of the acyl group between the r-carboxamide group of the glutamine residue in the protein and the primary amine is not hindered.
- the enzymes of microbial origin, especially of actinomycetes, are particularly useful for preparing modifications in the practice of the present invention due to their relatively high heat and pH stability as compared to those of other sources.
- the ratio of IFN- ⁇ 2 or IFN- ⁇ 8 to the water-soluble polymer in the reaction for obtaining the above-mentioned modified product depends on the reaction method, but is usually from 0 ⁇ 001 to 001 to 1 by weight. It is selected from the range of 1,000, desirably 1: 0.01 to 100. Depending on the reaction method, if the temperature is significantly lower than this range, the bonding between IFN-2 or IFN-8 may significantly occur, while if the temperature is significantly higher than this range, the bonding between water-soluble polymers may occur. Is not preferred.
- the reaction temperature, pH and time should be set so long as IFN- ⁇ 2 and IFN- ⁇ 8 are not deactivated or decomposed and the progress of side reactions can be suppressed as much as possible.
- the temperature is 0 ° C. to 100 ° C.
- the pH is about 1 to 12
- the reaction time is 0.1 hour to 50 hours.
- modification with a water-soluble polymer exhibiting specific characteristics in terms of average molecular weight and molecular weight distribution depending on the purpose of use of the modified product of IFN- £ ⁇ 2 and / or 1 "1 ⁇ 0-8"
- a water-soluble polymer having characteristics that meet the purpose in preparing such a modified product. Since there are products provided with specific molecular weights and molecular weight distributions, it is possible to select from these commercially available preparations that meet the purpose and use them as materials.
- Japanese Unexamined Patent Publication No. 6-65302 and Japanese Patent No. 866889 disclose a method for producing pullulan having a desired average molecular weight and a molecular weight distribution by controlling the culture conditions of a microorganism having a pullulan-producing ability. And these methods are It is useful for preparing the material of the modification used in the present invention.
- modified products of 1FN-a2 and / or IFN- ⁇ 8 polysaccharides such as pullulan and ercinan essentially having maltotriose as a repeating unit, preferably having a molecular weight of 10,000 to 1,
- the modified product with the polysaccharide in the range of 00000, 000 is relatively superior in terms of high stability in a human organism ⁇ low antigenicity to a human organism, and is particularly advantageous in the present invention.
- IFN- ⁇ 2 and IFN-a8 modified by the above-mentioned reaction can be purified by subjecting them to purification means according to the purification method of natural or recombinant IFN- ⁇ 2 or IFN- ⁇ 8. Can be obtained as a standard purified to a desired level. Then, the resulting modified IFN- ⁇ 2 and IFN-8 obtained as described above are blended at a desired activity ratio, or if necessary, the above-mentioned natural type and recombinant subtype May be combined with one or more kinds selected from the group consisting of such that the activity ratio between IFN- 82 and IFN-a8 becomes a desired ratio.
- the composition containing IFN- ⁇ 2 and IFN- ⁇ 8 thus obtained may be used per se or according to the purpose, and may contain other suitable components such as carriers, buffers, stabilizers, solvents, and diluents. It can be used in various fields as a protein synthesis inhibitor gene expression enhancer after being mixed.
- the enhancer exerts a remarkable effect of suppressing cell abnormalities by expressing a protein synthesis-suppressing gene in a human body, and both IFN-2 and IFN-o8 contained in the enhancer are human. Since such a potentiator is widely used in pharmaceutical applications targeting blood, the enhancer can be used as an effective component of a pharmaceutical composition.
- the pharmaceutical composition according to the present invention together with the enhancer as an active ingredient, is usually physiologically acceptable, that is, a carrier, an excipient, a stabilizer, a solvent, a buffer, and the like usually used in the pharmaceutical field. And, if necessary, as a composition further containing one or more other physiologically active substances, in the form of a liquid, solid, semi-solid, etc. in an appropriate form according to the indication and application method.
- the stabilizer usable herein include serum albuminase. Proteins such as ratine, glucose, sucrose, and lac !, sugar, trehalose, sorby !, and carbohydrates such as multi-yl, mannyl, and lactyl!
- physiologically active substances which can be used in combination, such as buffers mainly composed of acid salts or phosphates, include, for example, nitrogen master hydrochloride-d-N-oxide, mercaptopurine, etoposide, actinomycin D, mitoxantrone hydrochloride , L-asparaginase, lentinan, acyclovir, etc., as well as IL-1, TNF and IFN-r.
- composition according to the present invention configured as described above is used for a disease in which the symptoms are treated, alleviated or prevented by directly or indirectly involving the expression of the protein-suppressing gene, that is, in the expression of the gene.
- Sensitive eg, immune system, hematopoietic tissue
- the administration route is appropriately selected from intravenous, intramuscular, subcutaneous, intradermal, intraperitoneal, transdermal, oral and the like depending on the target disease.
- the dosage depends on the age of the subject, the type of disease, the condition, and the route of administration.However, when the pharmaceutical composition is administered by intramuscular injection, the adult substance per adult, per day, The total amount is usually 1 million IU to 10 million IU, more preferably, 3 million IU to 6 million IU, in terms of international units, at intervals of one or more days while observing symptoms on a daily basis or while observing symptoms. It is administered while the patient is on the go. In the case of oral administration, one adult, usually at a dose of 10 IU to 2000 IU, preferably 20 IU to 800 IU, more preferably 40 IU to 400 IU per day, daily or symptomatically The drug is administered at intervals of one or more days while observing the drug.
- the enhancer induces the expression of the protein synthesis-suppressing gene more remarkably as compared with the case of IFN-2 or IFN- ⁇ 8 alone indicates that the enhancer is an IFN- ⁇ -sensitive cell. Means that the intracellular reaction when applied to the cell can be observed more clearly are doing. Therefore, the enhancer is used for analyzing the molecular mechanism in the cell when IFN- acts on the susceptible cell to induce the expression of the protein synthesis suppressing gene, for example, for analyzing the intracellular signal transduction system at the molecular level. It can be used advantageously as a research reagent.
- the synergistic effect of the enhancer depends exclusively on the structure of the transcriptional regulatory region of the gene of interest by the enhancer, and is usually not related to the gene expression product itself. This means that the transcriptional regulatory region of the gene targeted by the enhancer is isolated, and a recombinant DNA in which a gene (structural gene) encoding the desired protein is placed under the control is prepared. If the cells are stimulated with the enhancer after introducing the recombinant DNA into IFN-a-sensitive cells, the cells will remarkably express the target protein. As IFN-a-sensitive cells, human IFN-a receptor is naturally expressed on the cell surface, and human IFN-a receptor is expressed on the cell surface by recombinant DMA technology.
- the protein to be produced here may be of human origin, as long as the DNA encoding the protein is available, but may be of other origin, for example, non-human vertebrates, invertebrates, plants or plants. It may be of microbial origin. Therefore, the enhancer can be advantageously used as an inducer in the production of a recombinant protein.
- IFN-a2 and IFN-a8 have a synergistic effect in inducing the expression of a protein synthesis-suppressing gene. It is used for enhancing the inducing action when inducing the expression of a protein synthesis-suppressing gene, and conversely, IFN-8 and IFN- "2 are used to enhance the protein synthesis-suppressing gene. Based on this fact, the present invention relates to the use of IFN- ⁇ 2 or IFN-a8 as an active ingredient for enhancing the inducing action when inducing expression. And a method for enhancing the expression of the gene using any one or both of the subtypes. .
- the enhancer and the enhancer method according to the present invention can be advantageously used in various fields such as pharmaceuticals, research reagents, and protein production where the enhancer can be used.
- the configuration of the expression enhancer disclosed in the present invention can also be applied to gene therapy. That is, DNA encoding IFN- ⁇ 2 and IFN-1 or 8 can be introduced into a vector derived from a virus such as a retrovirus, an adenovirus, or an adeno-associated virus, according to ordinary gene therapy.
- the DNA After linking the DNA to another base sequence as necessary, the DNA is embedded in a ribosome such as a kachi nick polymer or a membrane-fused liposome, and in this state, it is sensitive to the expression of a protein synthesis suppressor gene. Inject directly into patients with the disease. Alternatively, after incorporating the DNA into an appropriate vector, the DNA is introduced in vitro into lymphocytes collected from the patient, and this is autotransplanted into the patient. In addition, it is also advantageous to adjust the ratio of the expression level of each subtype by manipulating the DNA encoding each subtype under the control of transcription regulatory regions having different transcription activities. Can be implemented.
- a ribosome such as a kachi nick polymer or a membrane-fused liposome
- IFN-2 and IFN- ⁇ 8 are present in the body of a patient who has undergone such gene therapy, the treatment and alleviation of the diseases exemplified above can be achieved.
- the general procedure for implementing these gene therapies is described in, for example, Takashi Shimada, Izumi Saito, and Toshiya Ozawa, “Experimental Medicine Separate Volume Bio Manual UP Series Basic Techniques for Gene Therapy” (1996, Yodo Issuance).
- IFN- ⁇ 2 expression plasmid was prepared in this manner. This plasmid was introduced into Escherichia coli combi-tent cells (Toyobo Co., Ltd.,“ BL21 (DE3) ”) by a conventional method. Thus, an IFN-a2 producing transformant was obtained.
- the amplified DNA fragment was inserted into the downstream of the promoter of an expression vector for Escherichia coli (available from Toyobo Co., Ltd., trade name " ⁇ - 3a") by an ordinary method.
- an IFN-8 expression plasmid was prepared.
- This plasmid was introduced into an Escherichia coli enterocompetent cell ("BL21 (DE3)", sold by Toyobo Co., Ltd.) by an ordinary method to obtain an IFN-8-producing transformant.
- a portion of the gel-filtered purified fraction obtained from each transformant was subjected to reduced carboxamide methylation by a conventional method, followed by Edman degradation to decode the amino acid sequence from the N-terminal to the 30th residue. did.
- the purified fraction obtained from the 1FN-a2-producing transformant had a N-terminal methionine, and the subsequent sequence was the amino acid sequence of IFN-2 shown in SEQ ID NO: 1 in the sequence listing (database "Swiss Plot"). , Except for the signal peptide in the access code P01563 ”). It completely matched the amino acid sequence at the terminal (amino acids 24 to 52).
- the ⁇ -terminal is methionine
- the subsequent sequence is the amino acid sequence of 1FN-8 shown in SEQ ID NO: 2 in the sequence listing (database “Swiss Plot”, Except for the signal peptide in the access code [ ⁇ 32881], it completely matched the amino acid sequence (amino acids 24 to 52) at the ⁇ end except for the signal peptide. From the above results, it was confirmed that the two purified electrophoretically obtained samples obtained in the present experiment were IFN-2 and IFN- ⁇ 8, respectively.
- the IFN- ⁇ sample serial dilutions of twice the purified IFN- ⁇ subtype obtained in Experiment 11 (b) were used, and the IFN- ⁇ international standard “Ga23-901-532” ( 25, OOOI UZ ampoule, obtained from the US National Institutes of Health) were used, and the dilution ratio was determined when each of them inhibited CPE by 50%. From the obtained results, the antiviral activity (IU Zml) of the purified IFN- or subtype preparation in Experiment 1-1 (b) was calculated. On the other hand, separately from this, the protein content of the purified IFN- ⁇ subtype preparation in Experiment 1-1 (b) was measured according to the Lori method.
- HepG2 cells (ATCC HB-8065), an established cell line derived from human hepatocytes, are cultured in RPMI1640 medium containing 10% (vZv) fetal serum until the desired cell number is reached by the usual method. As a result, a cell suspension having a cell density of 1 ⁇ 10 5 ml was prepared. The cell suspension was injected one 0Q ⁇ l per Ueru in 96-well microphone port plate, in 5% (vZv) C0 2 incubator primary, cultured for 48 hours at 37 ° C.
- IFN-a2 and IFN-8 were converted to 10: 0, 8: 2, 6: 4, 5: 5, 4 : 6, 2: 8, or 0:10, and a mixed solution of IFN-2 / IFN-1 ⁇ 8 having a calculated total IFN- ⁇ activity of 1 ⁇ 10 4 IUZml was prepared. Each mixture was serially diluted twice in the above medium. Incidentally, the weight ratio of IFN-a2 and IFN-a8 in the mixed solution prepared here was calculated as 10 based on the specific activity obtained in Experiment 11 (c). 0: 0, 94: 6, 86:14, 81:19, 74:26 and 51:49, and 0: 100.
- a system without the IFN- ⁇ treatment and VSV treatment was set up and cultured for the same time, while starting from the same number of cells per 1 L as above.
- the same three sets were provided for all culture systems.
- cells were collected from each well, the number of viable cells was measured for each well by a conventional method, and the average value was determined for each system. Based on the results, a survival curve of HepG2 cells (a plot of the number of viable cells against the dilution ratio of the mixture) was prepared for each IFN-a2 / IFN- ⁇ 8 mixture.
- each IFN- ⁇ 2 and IFN- ⁇ 8 mixture showed a 50% CPE (cytopathic effect) of VSV against HepG2 cells based on the dilution factor when maintaining the survival of HepG2 cells at 50% of the control cell number.
- the average value of the concentration of each of the mixed solutions ( 5. , IUZ ml as the sum of calculated IFN- ⁇ activities per ml) was calculated.
- the calculated values were converted to multivariate values described in Ti-Shi-Chou, "Synergism 'and' Antagonism 'in'Chemotherapy” (published by Academic Press, 1991), pp. 61-102.
- IFN- ⁇ 2 and IFN- ⁇ 8 exert remarkable synergistic effects in the expression of antiviral activity when they coexist at a predetermined activity ratio.
- This fact indicates that when IFN- ⁇ 2 and IFN- ⁇ 8 coexist at this activity ratio.
- the cell suspension was injected by 1 ml per Ueru in 24-well microphone port plate, in 5% (v / v) C0 2 incubator one, obtained at 37 ° C for the experiment were cultured for 48 hours 1 one 1 (a) IFN- ⁇ 2 and IFN- ⁇ 8 were converted to 10: 0, 8: 2, 6: 4, 5: 5, 4: 6, 2: 8, or 0 : An IFN-a2ZIFN-8 mixed solution containing an activity ratio of: 10 and a total of 200 IUZml of IFN- ⁇ activity calculated was prepared.
- the cells were collected from each well, suspended in PBS, and then freeze-thawed to extract the cells, thereby obtaining a 100 I cell extract.
- the 2-5% synthase activity in these cell extracts was measured using a commercially available kit for measuring the enzyme activity (manufactured by Eiken Chemical Co., Ltd., trade name “2-5 ⁇ Kitsueiken '”).
- the amount was determined as 2-5 mass (pmol / dl) produced by the action of the enzyme, and the average value was determined for each system.
- the value obtained by subtracting the value of the control system from the value of the IFN- ⁇ -treated system was evaluated as the 2-5 ⁇ synthase inducing activity exhibited by each sample.
- a purified salt of IFN- ⁇ 2 and IFN-8 obtained by the methods of Experiments 11 (a) to 11 (b) was added to a physiological saline solution containing 1 ° / o (wZv) of hydrous crystalline trehalose as a stabilizer. After membrane concentration of the product by a conventional method, the solution was dissolved in such a manner that the activity ratio between the two became 2: 1 in terms of international units, and the calculated total IFN- ⁇ activity became 1 ⁇ 10 6 IU / ml. The solution was removed by microfiltration according to a conventional method to obtain a liquid preparation.
- This product has excellent stability and is sensitive to the expression of protein synthesis suppressor gene. It is a therapeutic agent for various diseases in the immune system, hematopoietic tissue, circulatory organ, skin tissue, digestive system, nervous system, muscle, etc. It is useful as a stock solution for producing a prophylactic agent. In addition, this product Can also be used as research reagents and inducers in the production of recombinant proteins.
- Example 2 Pharmaceutical stock solution
- a human IFN- ⁇ solution derived from BALL-1 cells was applied to anti-human HFN- ⁇ monoclonal antibody column chromatography (carrier: Lonza “ ⁇ -2 Sepharose”).
- Analysis by a conventional method revealed that the subtype of human HFN- ⁇ in this purified sample was substantially composed of IFN- ⁇ 2 and IFN-of 8, and the activity ratio of both subtypes in the purified sample was in international units. It was about 1: 1 in conversion.
- the above purified human HFN- sample was dialyzed against PBS, the internal solution of the dialysate was collected, concentrated by a conventional method, and then mixed with a physiological saline solution containing 1% (wZv) of hydrous trehalose as a stabilizer.
- the IFN- ⁇ activity was adjusted to 5 ⁇ 10 6 IUZml, and the bacteria were removed by microfiltration according to a conventional method to obtain a liquid preparation.
- This product has excellent stability and is sensitive to the expression of protein synthesis suppressor gene. It is a remedy and palliative for various diseases in the immune system, hematopoietic tissue, circulatory organ, skin tissue, digestive system, nervous system, muscle, etc. It is useful as a stock solution for producing a prophylactic agent. This product can also be used as a research reagent or as an inducer in the production of recombinant proteins.
- Example 3 Stock solution for drug production
- the purified samples of IFN-2 and IF ⁇ - ⁇ 8 obtained according to the methods of Experiments 11 (a) to 1-1 (b) were membrane-concentrated by a conventional method, and then were subjected to PBS ( PH 7.0). After dilution, a solution of each subtype having a concentration of 2 mgZml was prepared.
- This purified pullulan powder was dissolved in PBS (pH 7.0) to prepare a solution having a concentration of 20 mg / ml.
- This pullulan solution and a solution of cyanuric chloride in acetone adjusted to a concentration of 1% (wZv) were mixed at a volume ratio of 30: 1, and the mixture was incubated under ice-cooling for 2 hours with gentle stirring. The reaction was allowed to proceed, and the ripples were activated by cyanuric chloride.
- the reaction mixture containing cyanuric chloride-activated pullulan and the solution of 1 FN-2 or IFN-a8 obtained above were mixed at a volume ratio of 1: 1 and gently stirred.
- each of the obtained fractions containing the pullulan-binding subtype was subjected to chromatography using a polyclonal antibody column according to a conventional method.
- the polyclonal antibody column was prepared by a conventional method using a heron anti-human HFN-polyclonal antibody obtained using the purified human IFN- ⁇ sample obtained as a method in Example 2 as an antigen. used.
- the fractions bound to the polyclonal antibody column were collected to obtain purified samples of the pullulan binding subtypes (IFN-a2 and IFN-a8, respectively).
- the IFN- ⁇ activity of the sample was measured by a conventional method, and the two were mixed so that the activity ratio of IFN-a2 and IFN-a8 became 1: 1 in terms of international units.
- Dialysis was performed against physiological saline containing 1% (wZv) of hydrous crystalline trehalose as a stabilizer. The dialysis solution was collected, adjusted with the above-mentioned trehalose-containing physiological saline so that the IFN-a activity became 5 ⁇ 10 4 IUZml, and sterilized by microfiltration to obtain a solution.
- This product which has excellent characteristics in terms of stability in vivo and low antigenicity to the living body, is sensitive to the expression of protein synthesis suppressor genes, and is suitable for the immune system, hematopoietic tissue, circulatory organ, skin tissue, It is useful as an undiluted solution for the manufacture of therapeutic agents for various diseases in the digestive system, nervous system, muscles, etc.
- This product can also be used as a research reagent or an inducer in the production of recombinant proteins.
- Example 4 Stock solution for drug production
- the purified human HFN- standard prepared by the method of Example 2 in place of IFN-2 or IFN-a8 in the reaction of cyanuric chloride-activated pullulan with IFN-a2 or IFN-8 shown in Example 3 was used.
- a modification reaction with pullulan was carried out according to Example 3 except for using, followed by purifying the reaction product according to Example 3 by gel filtration chromatography and antibody column chromatography.
- the subtype of human HFN-a in this purified sample is substantially composed of pullulan-bound IFN-a2 and pullulan-bound IFN-a8.
- the activity ratio of both subtypes was about 1: 1 in terms of international units.
- This purified sample was dialyzed against a physiological saline solution containing 1% (wZV) of hydrated crystalline trehalose as a stabilizer.
- the dialysis solution was collected, adjusted with the above-mentioned trehalose-containing physiological saline so that the IFN-activity became 1 ⁇ 10 5 IUZml, and removed by microfiltration to obtain a liquid preparation.
- This product which has excellent characteristics in terms of stability in vivo and low antigenicity to the living body, is sensitive to the expression of protein synthesis suppressor genes, and is suitable for the immune system, hematopoietic tissue, circulatory organ, skin tissue, Diseases in the digestive system, nervous system, muscles, etc.
- Each of the stock solutions for drug production according to Examples 1 to 4 was dispensed into vials in a volume of 1 ml, lyophilized, and sealed.
- This product which has excellent stability, treats, alleviates or prevents various diseases in the immune system, hematopoietic tissue, circulatory system, skin tissue, digestive system, nervous system, muscle, etc., which are sensitive to the expression of protein synthesis suppressor gene. It is useful as a dry injection for use.
- Example 6 Ointment
- Carboxyvinyl polymer manufactured by Wako Pure Chemical Industries, Ltd., trade name: Hibisco 104
- hydrated crystalline trehalose in sterilized distilled water at concentrations of 1.4% (w Zw) and 2.0% (w w), and lumin, a cell activator was mixed to 5 mgZg.
- the mixture obtained by adding and mixing the stock solution of the pharmaceutical preparation according to Example 2 or 4 so as to have a concentration of 5 ⁇ 10 4 UZg was adjusted to H7.2 to obtain a gel.
- Example 7 Tablet Anhydrous crystalline maltose (manufactured by Hayashibara Shoji Co., Ltd., trade name “FINETOSE”) is mixed with the stock solution of the pharmaceutical preparation according to Example 2 or 4 so as to have a concentration of 1 ⁇ 10 3 I UZg. To give tablets of about 200 mg per tablet.
- This product which has excellent ingestibility and stability, treats various diseases in the immune system, hematopoietic tissue, circulatory system, skin tissue, digestive system, digestive system, nervous system, muscle, etc., which are sensitive to the expression of protein synthesis suppressing gene. It is useful as a tablet for oral administration for relief or prevention.
- the present invention indicates that when IFN- ⁇ 2 and IFN- ⁇ 8, which are subtypes of arboreal H FN- ⁇ , coexist, they exhibit a synergistic effect in inducing the expression of a protein synthesis-suppressing gene.
- the expression enhancer of the protein synthesis-suppressing gene of the present invention uses the subtype of human HFN- ⁇ , which is currently widely used as a drug for humans, as an active ingredient, it is useful for pharmaceutical use, especially for protein synthesis.
- the present invention can be advantageously used for medicinal use for various diseases in which symptoms are treated, alleviated or prevented by directly or indirectly involving the expression of a suppressor gene.
- the expression enhancer is also useful as a research reagent for elucidating the molecular mechanism leading to IFN activity expression, and as an inducer in the production of recombinant proteins.
- the present invention is an invention having such remarkable functions and effects, and is a very significant invention that contributes to the art.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- AIDS & HIV (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002395324A CA2395324A1 (en) | 2000-10-27 | 2001-09-26 | Expression potentiator for protein synthesis regulatory gene |
| EP01972507A EP1329223A4 (en) | 2000-10-27 | 2001-09-26 | EXPRESSION AMPLIFIER FOR PROTEIN SYNTHESIS OF REGULATORY GENES |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000-328539 | 2000-10-27 | ||
| JP2000328539 | 2000-10-27 | ||
| JP2001116710A JP2002201141A (ja) | 2000-10-27 | 2001-04-16 | 蛋白質合成抑制遺伝子の発現増強剤 |
| JP2001-116710 | 2001-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2002036153A1 true WO2002036153A1 (en) | 2002-05-10 |
Family
ID=26602905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2001/008390 Ceased WO2002036153A1 (en) | 2000-10-27 | 2001-09-26 | Expression potentiator for protein synthesis regulatory gene |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US6773701B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1329223A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002201141A (cg-RX-API-DMAC7.html) |
| KR (1) | KR100830268B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2395324A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI283582B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2002036153A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| JP4629964B2 (ja) * | 2003-09-12 | 2011-02-09 | 株式会社林原生物化学研究所 | ウシの消化器疾患治療剤 |
| CN101031655A (zh) | 2004-07-26 | 2007-09-05 | 陶氏环球技术公司 | 通过株工程改进蛋白表达的方法 |
| EP1867340A4 (en) | 2005-03-10 | 2009-12-23 | Hayashibara Biochem Lab | THERAPEUTIC AGENT FOR TREATING DISEASES IN THE BOVINE DIGESTIVE SYSTEM |
| JPWO2007037098A1 (ja) * | 2005-09-27 | 2009-04-02 | 株式会社林原生物化学研究所 | 繁殖障害改善剤 |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| US9394571B2 (en) | 2007-04-27 | 2016-07-19 | Pfenex Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| CN104056254A (zh) * | 2013-03-18 | 2014-09-24 | 赛德医药科技股份有限公司 | 用以降低肝炎病患复发率的组合物 |
| US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5142199B2 (cg-RX-API-DMAC7.html) | 1972-09-04 | 1976-11-13 | ||
| GB2016015B (en) | 1978-01-22 | 1982-05-06 | Hayashibara Co | Method of preparing interferon and preparations containing interferon |
| JPS5639022A (en) | 1979-09-05 | 1981-04-14 | Hayashibara Biochem Lab Inc | Preparation of vaccine |
| JPS5654158A (en) | 1979-10-09 | 1981-05-14 | Hitachi Ltd | Control system for call waiting |
| JP2838800B2 (ja) | 1989-09-02 | 1998-12-16 | 株式会社林原生物化学研究所 | 減感作剤 |
| US5503828A (en) * | 1992-02-10 | 1996-04-02 | Interferon Sciences, Inc. | Alpha interferon composition and method for its production from human peripheral blood leukocytes |
| JP3232488B2 (ja) | 1992-08-20 | 2001-11-26 | 株式会社林原生物化学研究所 | プルラン高含有物とその製造方法並びに用途 |
| US5780021A (en) * | 1993-03-05 | 1998-07-14 | Georgetown University | Method for treating type 1 diabetes using α-interferon and/or β-i |
| JPH07163368A (ja) | 1993-12-15 | 1995-06-27 | Hayashibara Biochem Lab Inc | 組換えdnaとその組換えdnaを含む形質転換体 |
| EP0785276A4 (en) | 1994-09-29 | 2002-01-09 | Ajinomoto Kk | MODIFICATION OF A PEPTIDE AND A PROTEIN |
| JP3467515B2 (ja) * | 1994-11-01 | 2003-11-17 | 財団法人ルイ・パストゥール医学研究センター | インターフェロン活性の測定法 |
| MY125300A (en) * | 1999-02-26 | 2006-07-31 | Inst Of Molecular And Cell Biology | Synergistic combination for treatment of viral-mediated diseases |
-
2001
- 2001-04-16 JP JP2001116710A patent/JP2002201141A/ja active Pending
- 2001-09-26 US US09/962,625 patent/US6773701B2/en not_active Expired - Fee Related
- 2001-09-26 CA CA002395324A patent/CA2395324A1/en not_active Abandoned
- 2001-09-26 KR KR1020027008401A patent/KR100830268B1/ko not_active Expired - Fee Related
- 2001-09-26 EP EP01972507A patent/EP1329223A4/en not_active Ceased
- 2001-09-26 WO PCT/JP2001/008390 patent/WO2002036153A1/ja not_active Ceased
- 2001-10-15 TW TW090125438A patent/TWI283582B/zh not_active IP Right Cessation
-
2004
- 2004-02-13 US US10/777,081 patent/US7189389B2/en not_active Expired - Fee Related
Non-Patent Citations (5)
| Title |
|---|
| DATABASE CAPLUS [online] AMERICAN CHEMICAL SOCIETY (ACS)(COLUMBUS, OHIO, USA); accession no. STN Database accession no. 114:4605 * |
| DATABASE CAPLUS [online] AMERICAN CHEMICAL SOCIETY (ACS)(COLUMBUS, OHIO, USA); accession no. STN Database accession no. 132:150470 * |
| SCHILLER J.H. ET AL.: "Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle", J. BIOL. RESPONSE MODIF., vol. 9, no. 4, 1990, pages 368 - 377, XP002907459 * |
| See also references of EP1329223A4 * |
| YAMAOKA T. ET AL.: "Biologic and binding activities of IFN-alpha subtypes in ACHN human renal cell carcinoma cells and Daudi Burkitt's lymphoma cells", J. INTERFERON CYTOKINE RES., vol. 19, no. 12, 1999, pages 1343 - 1349, XP002907458 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1329223A1 (en) | 2003-07-23 |
| KR100830268B1 (ko) | 2008-05-16 |
| US6773701B2 (en) | 2004-08-10 |
| US20040197307A1 (en) | 2004-10-07 |
| US7189389B2 (en) | 2007-03-13 |
| CA2395324A1 (en) | 2002-05-10 |
| KR20020065620A (ko) | 2002-08-13 |
| EP1329223A4 (en) | 2005-04-20 |
| JP2002201141A (ja) | 2002-07-16 |
| US20030039629A1 (en) | 2003-02-27 |
| TWI283582B (en) | 2007-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100537558B1 (ko) | 인터류킨-18 결합 단백질 | |
| KR100496460B1 (ko) | 폴리펩티드 | |
| EA014157B1 (ru) | РЕКОМБИНАНТНЫЕ МУТАНТЫ ИНТЕРФЕРОНА α2 (IFNα2) | |
| JPH07503851A (ja) | 改良インターフェロン及びヒトの末梢血液白血球からのその製造方法 | |
| CN103483443A (zh) | 重组人干扰素样蛋白 | |
| KR100237936B1 (ko) | 인터루킨-1 길항제 | |
| JP2003327542A (ja) | インターフェロン−γの産生を誘導するポリペプチド | |
| US7189389B2 (en) | Pharmaceutical composition of human interferon-α2 and interferon α8 subtypes | |
| EP1326628B1 (en) | Chemokine mutants in the treatment of multiple sclerosis | |
| US6368845B1 (en) | Polypeptides having L-asparaginase activity | |
| AU2002215919A1 (en) | Chemokine mutants in the treatment of multiple sclerosis | |
| JP3109018B2 (ja) | インターフェロン−γの産生を誘導する蛋白質 | |
| US7301005B2 (en) | Immunomodulatory peptides derived from heat shock proteins and uses thereof | |
| US6207641B1 (en) | Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases | |
| CA2400143C (en) | Recombinant conglutinin and producing method thereof | |
| US6774220B1 (en) | Compounds having lectinic properties and their biological applications | |
| CA2229739C (en) | Recombinant conglutinin and producing method thereof | |
| JPH09157180A (ja) | 感受性疾患剤 | |
| JPH11240898A (ja) | ポリペプチド |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 2395324 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1020027008401 Country of ref document: KR |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2001972507 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1020027008401 Country of ref document: KR |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWP | Wipo information: published in national office |
Ref document number: 2001972507 Country of ref document: EP |